6-K 1 giva_ph_2_fpi_pr_-_02-17.htm 6-K 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

 

 

Commission File Number: 001-39173

 

 

NovaBridge Biosciences

2440 Research Boulevard, Suite 400

Rockville, MD 20850

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒                Form 40-F ☐

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

On February 17, 2026, NovaBridge Biosciences issued a press release, a copy of which is furnished herewith as Exhibit 99.1.

 

EXHIBIT INDEX

 

Exhibit No.

Description

 

 

99.1

Press Release - NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

NovaBridge Biosciences

 

 

 

By

:

/s/ Xi-Yong Fu

 

Name

:

Xi-Yong (Sean) Fu

 

Title

:

Chief Executive Officer

 

Date: February 17, 2026